Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01741792 is registered in ClinicalTrials.gov with Amgen Research (Munich) GmbH as lead sponsor.

NCT NCT01741792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01741792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Amgen Research (Munich) GmbH
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2012
Completion date
September 30, 2015
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma